The emerging field of telerobotic surgery is gaining momentum, and SS Innovations International (NASDAQ: SSII) is establishing a significant presence in this niche, according to a recent MedTech Dive report that examined the technology's global development and the regulatory and infrastructure questions surrounding remote surgery. The article, which highlighted SS Innovations alongside larger medical-device companies and emerging robotics developers (https://ibn.fm/4ZLvL), underscores the company's growing relevance in a market that is moving from isolated demonstrations toward broader clinical adoption.
At the heart of this positioning is the SSi Mantra system, which has accumulated substantial experience in telesurgery. As of September 28, 2026, the company reported 195 robotic telesurgeries, including cardiac procedures and long-distance operations. The installed base of SSi Mantra systems reached 244 units, up 45% from the end of 2025, while cumulative procedures across all systems totaled 14,503. These figures illustrate not only adoption but also the system's increasing use in complex, remote procedures.
For SS Innovations, the significance lies in the validation of its technology and the potential to shape the future of surgery. CEO Dr. Sudhir Srivastava, a cardiac surgeon, told MedTech Dive that robotic surgery is inherently a form of teleoperation and that the central technical question is how much distance can be introduced without compromising responsiveness. This insight is critical as the company pushes the boundaries of remote surgery, where latency and reliability are paramount. The SSi Mantra's performance in cardiac procedures, which demand exceptional precision, demonstrates its capability in high-stakes environments.
The company's expansion into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka and a new program at HCG Hospital in Ahmedabad, signals a strategic push into diverse healthcare markets. This global footprint not only diversifies revenue but also generates clinical data that could support regulatory submissions. SS Innovations is currently pursuing U.S. FDA clearance and European Union CE marking, which, if successful, would open access to two of the world's largest medical device markets. The implications are substantial: regulatory approvals would accelerate adoption, attract partnerships, and potentially lower costs through economies of scale.
Investors and industry observers can track the company's progress through its newsroom at https://ibn.fm/SSII, which provides ongoing updates. The MedTech Dive article also noted that telerobotic surgery is advancing around the world, raising questions about whether the U.S. will embrace it. For SS Innovations, the answer may come sooner rather than later, as its clinical experience and international expansion create a compelling case for regulatory acceptance. As remote procedures gain ground, the company's early mover advantage in telesurgery could translate into a durable competitive edge, making its trajectory one to watch in the evolving surgical robotics landscape.
